LAVA Therapeutics To Present at the Oppenheimer 32nd Annual Healthcare Conference 2022
March 10 2022 - 6:30AM
LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage
biotechnology company focused on developing its proprietary
Gammabody™ platform of bispecific gamma delta T cell engagers
(bsTCEs) to transform the treatment of cancer, today announced that
Stephen Hurly, president and chief executive officer, will present
the latest company overview at the Oppenheimer 32nd Annual
Healthcare Conference 2022. The conference is being conducted in a
virtual format and the presentation will take place on Thursday,
Mar. 17, 2022 from 8:40 – 9:10 a.m. ET.
The recording will be available following the
conference under the "Events" tab on the investor relations section
of the LAVA Therapeutics website at:
https://ir.lavatherapeutics.com/news-events/events.
About LAVA
Therapeutics LAVA Therapeutics N.V. is an
immuno-oncology company utilizing its
proprietary Gammabody™ platform to develop a
portfolio of bispecific gamma delta T cell engagers (bsTCEs)
for the potential treatment of solid tumors and hematological
malignancies. The company’s innovative approach utilizes bispecific
antibodies engineered to selectively kill cancer cells via the
triggering of Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor
effector functions upon their cross-linking to tumor-associated
antigens. A Phase 1/2a clinical study evaluating LAVA-051 in
patients with certain hematological malignancies is currently
enrolling (NCT04887259). The company currently anticipates
additional data from the Phase 1 dose escalation phase of the
LAVA-051 study in the second quarter of 2022 and data from the
Phase 2a expansion cohorts in the second half of 2022. A Phase 1/2a
clinical study to evaluate LAVA-1207 in patients with metastatic
castration-resistant prostate cancer (mCRPC) is enrolling with data
from the Phase 1 dose escalation phase of the trial expected in the
second half of 2022 and data from the Phase 2a expansion cohort
expected in the first half of 2023. For more information, please
visit www.lavatherapeutics.com and follow us
on LinkedIn, Twitter and YouTube.
CONTACTEdward SmithChief
Financial Officerir@lavatherapeutics.com
Catherine
Day+1-917-763-2709catherine@newdaybioconsulting.com
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Apr 2023 to Apr 2024